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Medium-Term Complications Associated
With Coronary Artery Aneurysms After
Kawasaki Disease: A Study From the
International Kawasaki Disease Registry
Brian W. McCrindle , MD, MPH; Cedric Manlhiot, PhD; Jane W. Newburger
, MD, MPH;
Ashraf S. Harahsheh, MD; Therese M. Giglia, MD; Frederic Dallaire, MD, PhD; Kevin Friedman, MD;
Tisiana Low, MD; Kyle Runeckles, MSc; Mathew Mathew, MSc; Andrew S. Mackie, MD, MS; Nadine F. Choueiter, MD;
Pei-Ni Jone, MD; Shelby Kutty, MD, PhD; Anji T. Yetman, MD; Geetha Raghuveer, MD; Elfriede Pahl, MD;
Kambiz Norozi, MD, PhD; Kimberly E. McHugh, MD; Jennifer S. Li, MD, MHS; Sarah D. De Ferranti, MD, MPH;
Nagib Dahdah, MD; for the International Kawasaki Disease Registry*
BACKGROUND: Coronary artery aneurysms (CAAs) may occur after Kawasaki disease (KD) and lead to important morbidity
and mortality. As CAA in patients with KD are rare and heterogeneous lesions, prognostication and risk stratification are
difficult. We sought to derive the cumulative risk and associated factors for cardiovascular complications in patients with
CAAs after KD.
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METHODS AND RESULTS: A 34-institution international registry of 1651 patients with KD who had CAAs (maximum CAA Z
score ≥2.5) was used. Time-to-event analyses were performed using the Kaplan–Meier method and Cox proportional
hazard models for risk factor analysis. In patients with CAA Z scores ≥10, the cumulative incidence of luminal narrowing
(>50% of lumen diameter), coronary artery thrombosis, and composite major adverse cardiovascular complications at
10 years was 20±3%, 18±2%, and 14±2%, respectively. No complications were observed in patients with a CAA Z score
<10. Higher CAA Z score and a greater number of coronary artery branches affected were associated with increased risk
of all types of complications. At 10 years, normalization of luminal diameter was noted in 99±4% of patients with small
(2.5≤Z<5.0), 92±1% with medium (5.0≤Z<10), and 57±3% with large CAAs (Z≥10). CAAs in the left anterior descending and
circumflex coronary artery branches were more likely to normalize. Risk factor analysis of coronary artery branch level outcomes was performed with a total of 893 affected branches with Z score ≥10 in 440 patients. In multivariable regression
models, hazards of luminal narrowing and thrombosis were higher for patients with CAAs of the right coronary artery and
left anterior descending branches, those with CAAs that had complex architecture (other than isolated aneurysms), and
those with CAAs with Z scores ≥20.
CONCLUSIONS: For patients with CAA after KD, medium-term risk of complications is confined to those with maximum CAA Z
scores ≥10. Further risk stratification and close follow-up, including advanced imaging, in patients with large CAAs is warranted.
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CLINICAL PERSPECTIVE
What Is New?

• Medium-term cardiac complications of coronary artery aneurysms secondary to Kawasaki
disease are relatively frequent but generally limited to patients with maximum coronary artery Z
scores >10.
• While patients with coronary artery Z scores
>10 were previously thought to represent a
common risk category, increased risk profile
was observed for patients with coronary artery
Z scores >20.
• Physical properties of coronary artery aneurysms are associated with the risk of complications potentially by affecting blood rheology.

What Are the Clinical Implications?

• While still requiring ongoing follow-up, patients
with small or medium coronary artery aneurysms can likely be managed with low-intensity,
antiplatelet-based thromboprophylaxis and are
unlikely to need anticoagulation.
• Given the substantial risk of complications,
combined thromboprophylaxis with both anticoagulation and antiplatelet agents should
be considered in patients with giant coronary
artery aneurysms, particularly those with coronary artery Z scores >20.
Downloaded from http://ahajournals.org by on August 13, 2020

Nonstandard Abbreviations and Acronyms
AHA
CAA
CI
IKDR
IQR
IVIG
KD
LAD
LCX
LMCA
MI
RCA
REDCap

K

American Heart Association
coronary artery aneurysm
cumulative incidence
International Kawasaki Disease
Registry
interquartile range
intravenous immunoglobulin
Kawasaki disease
left anterior descending coronary
artery
left circumflex artery
left main coronary artery
myocardial infarction
right coronary artery
Research Electronic Data Capture

awasaki disease (KD) is a pediatric systemic vasculitis with a predilection for the coronary arteries.
Coronary artery aneurysms (CAAs) are recognized

as the most important complication of KD, leading to
significant morbidity and mortality. As a result, KD is
now thought to be the leading cause of acquired heart
disease in children of developed countries.1,2 Despite
optimal acute management, CAAs still develop in ≈4%
of cases. The prevalence of CAAs increases to 25% if
the diagnosis of KD is missed or treatment is delayed.1
Thrombosis in large CAAs can lead to total occlusion
and myocardial infarction (MI) and sudden death.1 In
the long-term, CAAs accompanied by chronic inflammation and luminal myofibroblastic proliferation have
the potential to reduce the size of CAA, but the process
may eventually cause luminal narrowing. Additionally,
nonocclusive organized thrombus and recanalized occlusive thrombus can contribute to luminal narrowing.1
An angiographic study published in 1986 found that
there was low prevalence of occlusion and stenosis
early on after the acute KD period, and that complications often occurred at least 1 year from disease
onset.3 These findings were later supported by a large
historical Japanese cohort reported by Kato et al.4 This
highlights the importance of uninterrupted long-term
follow-up with serial imaging to determine the risks of
cardiac complications in patients with KD and inform
tailored management strategies.
Given the heterogeneity of patients with CAAs and
their rarity at any single institution, there are a paucity of
data available to inform more precise risk stratification
for outcomes in this population. In addition, a limited
number of risk factors have been identified for adverse
outcomes, which has impeded the development and
evaluation of long-term surveillance and management
strategies calibrated to individual risk. Therefore, we
sought to determine the cumulative risk and associated factors for adverse cardiovascular outcomes for
patients with KD and CAAs using data from the IKDR
(International Kawasaki Disease Registry), a large, curated, multi-institutional registry including medium- to
long-term clinical follow-up.

METHODS
Because of the sensitive nature of the data collected
for this study, requests to access the data set from
qualified researchers trained in human subject confidentiality protocols may be sent to the research ethics
board of The Hospital for Sick Children at researchethics.board2@sickkids.ca and to the corresponding author of this study to initiate the process. Authorization
from all institutions who participated in this study will
be required to access the data set.

Study Population
Data for this study was collected by the IKDR, which
included 34 pediatric referral centers in Canada, the

J Am Heart Assoc. 2020;9:e016440. DOI: 10.1161/JAHA.119.0164402

McCrindle et al

United States, and Taiwan. To be eligible for the registry, patients younger than 18 years must have been
diagnosed with complete or incomplete KD between
1999 and 2017 and have at least 1 CAA with a maximum coronary artery Z score ≥2.5 at any time after
diagnosis based on the American Heart Association
(AHA) recommendations for risk stratification.1 Patients
seen at participating centers only for a single consultation (or in the acute phase only) and patients seen for
the first time at the reporting center >3 months after
the acute phase were not eligible for the registry. For
the purpose of this study, data harvest was performed
on March 1, 2018, and included all follow-up information up to December 31, 2017. Participating centers
were required to submit all cases that met all inclusion
criteria and none of the exclusion criteria, thus preventing potential selection bias.

Data Acquisition
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Data were retrospectively collected by participating centers and entered using centralized Research
Electronic Data Capture (REDCap) tools, which is a
secure, web-based application designed to support
data capture for research studies, hosted at SickKids
Hospital (Toronto, Canada).5 Personnel from the data
coordinating center (also hosted at SickKids Hospital)
reviewed patient data for eligibility and performed data
validation and verification. Participation in the IKDR
requires institutional review board or research ethics
board approval for the study at the US and Canadian/
Taiwanese sites, respectively, with the institutional review board/research ethics board approving a waiver
of consent for the collection of retrospective data.
SickKids Hospital was responsible for managing all bilateral data sharing agreements.

Data Collection
The IKDR collects deidentified information regarding
patient demographics, details of hospitalization for
the acute KD episode, short- and long-term management, imaging data, and complications. As per AHA
guidelines, patients with prolonged fever but ≤3 of the
classic clinical features of KD were classified as having
incomplete KD. Copies of all imaging reports (echocardiograms, angiograms, computed tomography scans,
and magnetic resonance imaging) were submitted to
the data coordinating center for centralized data extraction, and the coronary arteries of all patients were
characterized and classified. Serial absolute internal luminal diameters were retrieved from echocardiography
reports, and the measurements were adjusted for body
surface area (recalculated using the Haycock formula
for all patients to ensure consistency) by calculation
of Z scores using the Boston coronary artery Z score
equations (the left anterior descending artery [LAD]
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equation was used for the left circumflex artery [LCX]).2
Based on maximal Z score, CAAs were classified as
small (2.5≤Z<5), medium (5≤Z<10), and large (Z≥10), as
per 2017 AHA guidelines.1 Data extracted from written reports of imaging study included the number of
coronary artery branches with CAAs and the maximum CAA Z score ever reached. The coronary artery
architecture was classified as dilatation only, isolated
CAA in an otherwise normal vessel, isolated CAA in a
dilated vessel, or complex CAAs. Complex CAA was
defined as any coronary artery branch with >1 discrete
lesion or with CAAs extending into the bifurcation of
the left main coronary artery. The CAA location within
the branch, the CAA shape and length of the CAA
when reported, the CAA diameter to length ratio, and
the estimated CAA ellipsoid area (diameter multiplied
by length×0.80) were also assessed. Normalization of
CAA diameter was defined as the reduction of the internal diameter of a CAA during follow-up to achieve a
Z score <2.5.

Patient Outcomes
Complications of CAAs were defined as: (1) luminal
narrowing clinically reported as significant coronary
artery stenosis/obstruction confirmed on coronary artery angiography (>50% narrowing of lumen diameter);
(2) coronary artery revascularization either by catheterization or surgery; (3) coronary artery thrombosis
(occlusive or nonocclusive) diagnosed on any imaging modality; (4) MI reported clinically; and (5) major
adverse cardiac complications, including a composite of surgical or catheter-based revascularization, MI,
cardiac ischemia, heart transplantation, or death from
cardiac causes.

Statistical Analysis
Data are presented as means with SDs, medians with
interquartile ranges (IQRs), and frequencies as appropriate. Time-related freedom from outcomes was
calculated using the Kaplan–Meier method (presented
as cumulative incidence rate rather than freedom from
event). Patient follow-up intervals were censored at last
follow-up or death. Multivariable risk factor analysis
was performed using Cox proportional hazard analysis, with variable selection informed using bootstrap
resampling (500 random samples, P<0.05 to enter
and P<0.10 to remain).6 Variables with high reliability
(ie, selected in >50% of the random samples) were
then included in a multivariable Cox proportional hazard model. Backward selection of variables was then
used to obtain a final model. Proportional hazard assumption was tested by assessing the statistical significance of the time-dependent covariate (interaction
between the time component and each parameters) in
the regression models; none of which demonstrated
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a violation of the proportional hazard assumption. A
complete list of variables considered in the risk factor
analysis can be found in Table 1. Note that acetylsalicylic acid use was not included in risk factor analysis
given that >99% of patients were taking this medication, and long-term treatments (eg, antithrombotics,
β-blockers, and statins) were not included given their
time-varying nature. Pertinent negatives are reported.
For the analysis by affected coronary artery branch,
only branches with CAA maximal Z score ≥10 were included. While each branch is unique, patients could
have had >1 branch with CAA Z score ≥10. For this
analysis, adjustment for repeated measures (multiple branches included from the same patient) was
Table 1. Patients and CAA Characteristics Considered
in the Risk Factor Analysis for Cardiac Complications and
Outcomes
Risk Factors
Age at KD
Sex
Type of KD (complete/incomplete)
Arthritis at diagnosis
Laboratory values during acute phase
Hemoglobin, g/L
Hematocrit, %
ESR, mm/h
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White blood cell count, ×109/L
Platelets, ×109/L
Albumin, g/L
C-reactive protein, mg/L
Red blood cell count, ×1012/L
Aspartate transaminase, U/L
Alanine aminotransferase, U/L
Duration of fever before IVIGs
Total duration of fever
IVIG treatment
No. of IVIG doses
Intravenous steroids in the acute phase
Oral steroids in the acute phase
Infliximab in the acute phase
Any use of nonsteroidal anti-inflammatory drugs in the acute phase
Coronary artery branch
Maximum coronary artery Z score
Involvement of the LAD/LMCA/LCX bifurcation
Aneurysm architecture
Aneurysm location within coronary branch
Aneurysm shape
Aneurysm width to height ratio
Aneurysm estimated area
CAA indicates coronary artery aneurysm; ESR, erythrocyte sedimentation
rate; IVIG, intravenous immunoglobulin; KD, Kawasaki disease; LAD, left
anterior descending artery; LCX, left circumflex artery; and LMCA, left main
coronary artery.
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performed by including the model-based estimate
for the covariance matrix as a regression term in the
Cox proportional hazard model. Kaplan–Meier analyses were performed for up to 10 years postdiagnosis,
after which the number of patients remaining at risk
was deemed too low to generate valid estimates. All
statistical analyses were performed using SAS version
9.4 (SAS Institute Inc).

RESULTS
Patient and CAA Characteristics
A total of 1651 patients were included in this analysis,
of whom 1184 (72%) were men, as expected given the
sex distribution of KD. The median age at diagnosis
was 2 years (IQR, 0.67–4.67 years; range 1 month–
17.9 years), with 744 (45%) aged between 1 and
5 years. Patients had a median fever duration of 9 days
(IQR, 7–13 days), and 973 of 1633 (60%) had complete
KD. Maximum Z scores of any of the 4 coronary artery
branches (right coronary artery [RCA], left main coronary artery [LMCA], LAD, or LCX) were used to categorize patients as having small 854 (52%), medium 357
(22%), and large 440 (27%) CAAs. Notably, a greater
degree of coronary artery complications was associated with extremes of the age spectrum (younger and
older), having incomplete rather than complete KD,
longer duration of fever before treatment, nonresponse
to first treatment with intravenous immunoglobulins
(IVIGs) as indicated by need for immunosuppressive
therapy beyond the initial IVIG cycle, and longer total
duration of fever. Complete patient characteristics
stratified by degree of coronary artery involvement are
presented in Table 2.

Complications of CAAs
Median duration of follow-up was 2.1 years (IQR, 0.9–
6.4; 5th–95th percentile: 0.1–12.5) (total of 6366 patient-years of follow-up) for all patients. Follow-up was
substantially longer for patients with large CAAs, with a
median of 5.2 years (IQR, 1.9–8.9; 5th–95th percentile:
0.3–14.3) (P<0.001). No complications were reported
for patients with small CAAs. Only 1 patient with a medium CAA (maximum Z score of 8.5) experienced a
cardiac complication (chronic cardiac ischemia resulting in heart failure and death); this patient happened to
have CAAs in all 4 coronary artery branches. Figure 1
presents the cumulative incidence (CI) of 6 major
complications in patients with large CAAs, including
luminal narrowing (10-year CI, 20±3%), coronary artery interventions (10-year CI, 10±2%), coronary artery
thrombosis (10-year CI, 18±2%), MI (10-year CI, 5±2%),
composite major adverse cardiac complications (10year CI, 14±2%), and death from cardiac causes or
heart transplantation (10-year CI, 2±1%).
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Table 2. Patient Characteristics Stratified by Maximum Degree of Coronary Artery Involvement
No.

All Patients

No.

Small CAA

No.

Medium CAA

No.

Large CAA

P Value

1651

1184 (72%)

854

623 (73%)

357

245 (69%)

440

316 (72%)

0.32

Age at diagnosis, y

1651

2.0 (0.7–4.7)

854

2.4 (1.1–5.0)

357

1.5 (0.5–3.8)

440

1.4 (0.4–4.7)

<0.001

Age at diagnosis category, y

1651

Acute phase presentation
Men

854

357

440

<0.001

<0.5

282 (17%)

78 (9%)

76 (21%)

128 (29%)

0.5 to <1

240 (15%)

113 (13%)

61 (17%)

66 (15%)

1 to <5

744 (45%)

447 (52%)

155 (43%)

142 (32%)

5 to <10

306 (19%)

171 (20%)

56 (16%)

79 (18%)

79 (5%)

45 (5%)

9 (3%)

≥10
Any acute readmission

1508

223 (15%)

757

79 (10%)

331

44 (13%)

25 (6%)
420

100 (23%)

<0.001

Fever pre-IVIGs, d

1578

7 (5–10)

824

6 (5–8)

348

7 (5–10)

406

9 (6–14)

<0.001

Fever post-IVIGs, d

1527

1 (0–3)

783

1 (0–2)

344

1 (0–3)

400

1 (0–5)

<0.001

Total fever duration, d

1553

9 (7–13)

798

8 (6–10)

348

9 (7–12)

407

13 (9–17)

<0.001

Length of hospital stay, d

1576

5 (3–8)

802

4 (3–6)

352

5 (3–9)

422

8 (4–15)

<0.001

Conjunctivitis

1616

1462 (91%)

835

756 (91%)

354

317 (90%)

427

389 (91%)

0.75

Cervical lymphadenopathy

1616

653 (40%)

835

367 (44%)

354

130 (37%)

427

156 (37%)

0.01

Rash

1618

1386 (86%)

837

717 (86%)

354

315 (89%)

427

354 (83%)

0.05

Erythema/edema of extremities

1593

978 (61%)

823

527 (64%)

348

206 (59%)

422

245 (58%)

0.08

Mucosal changes

1616

1237 (77%)

835

677 (81%)

354

256 (72%)

427

304 (71%)

<0.001

No. of KD symptoms

1597

828

351

418

0.006

1

56 (3%)

26 (3%)

12 (3%)

18 (4%)

2

175 (11%)

71 (8%)

48 (13%)

56 (13%)
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3

436 (26%)

208 (24%)

101 (28%)

127 (29%)

4

648 (39%)

363 (43%)

137 (38%)

148 (34%)

5

282 (17%)

160 (19%)

53 (15%)

Type of KD reported

1633

845

355

69 (16%)
433

<0.001

Complete

973 (60%)

549 (65%)

199 (56%)

225 (52%)

Incomplete

660 (40%)

296 (35%)

156 (44%)

208 (48%)

Arthritis

1384

170 (12%)

718

87 (12%)

310

24 (8%)

356

59 (17%)

0.002

Weight before first IVIG dose, kg

1401

13 (9–19)

700

13 (10–19)

309

12 (8–17)

392

11 (8–20)

<0.001

Duration of follow-up, y

1651

2.1 (0.9–6.4)

854

1.2 (0.4–3.4)

357

2.8 (1.0–6.3)

440

5.2 (1.9–8.9)

<0.001

Hemoglobin, g/L

1350

105.7±14.2

732

108.6±12.8

295

103.6±14.2

323

101.2±15.7

<0.001

Hematocrit, %

1300

0.31±0.04

716

0.32±0.04

282

0.31±0.04

302

0.30±0.04

<0.001

Red blood cell count, ×10 /L

1042

4.0 (3.6–4.3)

526

4.1 (3.8–4.4)

246

3.9 (3.6–4.3)

270

3.8 (3.4–4.2)

<0.001

White blood cell count, ×109/L

1358

16.1±6.8

729

14.9±5.7

303

16.6±6.7

326

18.2±8.4

<0.001

Platelets, ×109/L

1339

442±220

719

395±170

295

467±242

325

523±265

<0.001

ESR, mm/h

1166

62 (46–88)

647

60 (45–85)

257

61 (46–85)

262

70 (50–100)

<0.001

C-reactive protein, mg/L

1140

20 (9–84)

629

18 (8– 69)

246

20 (8–96)

265

25 (12–106)

0.004

Albumin, g/L

1003

31.6±6.4

553

33.1±6.2

222

30.8±6.1

228

28.8±6.2

<0.001

Aspartate transaminase, U/L

946

36 (25–58)

494

37 (27–61)

220

34 (24–55)

232

33 (24–53)

0.02

Alanine aminotransferase, U/L

1202

35 (19–74)

684

38 (20–90)

259

33 (18–64)

259

32 (19–57)

0.04

At least 1 IVIG course

1646

1592 (97%)

852

828 (97%)

357

350 (98%)

437

414 (95%)

No. of IVIG doses

1643

Laboratory values at admission

12

Acute treatment

852

357

434

0.03
<0.001

0

54 (3%)

24 (3%)

7 (2%)

23 (5%)

1

1009 (61%)

600 (70%)

207 (58%)

202 (46%)
(Continued)

J Am Heart Assoc. 2020;9:e016440. DOI: 10.1161/JAHA.119.0164405

McCrindle et al

Medium-Term Complications of Kawasaki Disease

Table 2. Continued
No.

All Patients

No.

Small CAA

No.

Medium CAA

No.

Large CAA

2

506 (31%)

214 (25%)

125 (35%)

167 (38%)

3

66 (4%)

14 (2%)

16 (5%)

36 (8%)

≥4

8 (1%)

0 (0%)

2 (1%)

P Value

6 (1%)

Infliximab

1642

214 (13%)

851

86 (10%)

355

51 (14%)

436

77 (18%)

Pentoxifylline

1591

7 (0.4%)

816

0 (0%)

346

2 (1%)

429

5 (1%)

<0.001
0.01

Immunotherapy

1591

46 (3%)

816

10 (1%)

346

11 (3%)

429

25 (6%)

<0.001

Any steroids

1594

342 (21%)

817

104 (13%)

348

73 (21%)

429

165 (38%)

<0.001

Oral steroids

1592

216 (14%)

817

58 (7%)

346

44 (13%)

429

114 (27%)

<0.001

Intravenous steroids

1525

288 (19%)

761

85 (11%)

336

62 (19%)

428

141 (33%)

<0.001

Small CAA: 2.5 ≤ Z < 5; Medium CAA: 5 ≤ Z < 10; Large CAA: Z ≥ 10.
CAA indicates coronary artery aneurysm; ESR, erythrocyte sedimentation rate; IVIG, intravenous immunoglobulin; and KD, Kawasaki disease.

Downloaded from http://ahajournals.org by on August 13, 2020

There were 8 deaths overall: 1 with medium and 7 with
large CAAs. The 1 patient with medium CAAs in all
4 branches (mentioned above) died of chronic ischemia 6 months after the acute phase. Four deaths
were secondary to MI (3 within 6 weeks of the acute
phase and 1 that occurred 18 months after the acute
phase). The other 3 patients died of noncardiac causes
(1 mitochondrial disorder and 2 trauma). In addition, 2
patients with large CAAs underwent heart transplantation at 5 months and 4 years after the acute phase. A
higher maximum CAA Z score and higher number of
coronary artery branches affected were strongly associated with the composite outcome of major cardiac
complications (Table 3).

Branch Level Outcomes
Given that the risk of complications was associated
with specific CAA characteristics (as opposed to
being determined solely at the patient level), risk factor analyses were performed at the coronary artery
branch level for branches with at least 1 CAA with a Z
score ≥10. CAAs with Z scores <10 were not included
in this analysis because of our finding that there was
no substantial risk of complications in those patients.
A total of 893 CAAs in 440 patients were included in
this analysis, with 370 (42%) in the LAD, 297 (33%) in
the RCA, 135 (15%) in the LCX, and 91 (10%) in the
LMCA. The majority (603, 68%) of branches included
had maximum CAA Z scores 10 to 19.9, 195 (22%) had
Z scores 20 to 29.9, 48 (5%) had Z scores 30 to 39.9
(5%), and 47 (5%) had Z scores ≥40. Complete details
of the architecture of CAAs by branch are presented in
Table 4. This analysis focused on 3 branch-level outcomes: narrowing of luminal diameter >50% of normal,
coronary artery thrombosis, and normalization of luminal diameter. Given that vascular interventions and MIs
may be a consequence of the first 2 categories, risk
factors are presumed likely to be the same. Vascular
interventions and MIs were not analyzed as separate
outcomes.

At 10 years, luminal narrowing affected 12±1% of
all branches with large CAAs, with substantially higher
rates of narrowing for CAAs in the RCA and the LAD
(versus LMCA and LCX) and in branches with CAAs
with Z scores ≥20 (Figure 2). The complete list of factors associated with luminal narrowing in multivariable
Cox regression models is provided in Table 5. Other
than CAA branch and higher CAA size, complex CAA
architecture was also associated with greater hazard of luminal narrowing. Some characteristics of the
acute phase were also associated with an increased
hazard of luminal narrowing, namely lower number of
IVIG doses (ie, cycles) during the acute phase, lower
serum albumin levels, and higher total number of days
of fever before treatment with IVIGs.
Thrombosis affected 11±1% of all branches with
large CAAs by 10 years, with a predilection for the RCA
and the LAD, and for branches with CAAs with Z score
≥20 (Figure 2). The complete list of factors associated
with coronary artery thrombosis in multivariable Cox
regression models is provided in Table 6. Factors associated with an increased risk of thrombosis included
greater maximum CAA Z score, no treatment with
IVIGs in the acute phase, complex CAA architecture,
and lower serum C-reactive protein in the acute phase.
Normalization of luminal diameter at 10 years occurred in 57±3% of branches with large CAAs, which
was substantially lower than the rate of normalization for
branches with medium (92±1%) or small CAAs (99±4%)
(Figure 3). Large CAAs in the LAD and LCX were more
likely to normalize in dimensions compared with those
in the RCA or LMCA, and the hazard of normalization
was inversely proportional to the maximum Z score
of the CAA (Figure 2). The complete list of factors associated with normalization of luminal diameter in the
multivariable regression model are shown in Table 7.
Other than coronary artery branch and the maximum
size of the CAA, factors associated with increased risk
of normalization were lower total CAA ellipsoid area,
treatment with IVIGs in the acute phase, female sex,
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Figure 1. Cumulative incidence calculated using Kaplan–Meier survival analysis of complications for patients with coronary
artery aneurysms after Kawasaki disease in patients with at least 1 lesion with a coronary artery Z score ≥10.
Dotted lines represent the estimated standard error around the cumulative incidence.

younger age at acute KD, incomplete KD, and lower
initial erythrocyte sedimentation rate.
CAA shape (saccular or fusiform/irregular), location
in the vessel (distal, extending, or proximal), and width
to height ratio were not associated with any cardiac
complications in multivariable models (although some
associations were statistically significant at the univariable level) (data not shown).

DISCUSSION
In this study, we report that the occurrence of luminal narrowing, coronary artery thrombosis, and major
adverse cardiac complications were nearly completely confined to patients with CAAs with Z scores
≥10. Importantly, in those patients, the risk continued
to increase over time, highlighting the importance of
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Table 3. Univariable Factors Associated With Composite
Risk Major Adverse Cardiac Complications in Cox
Proportional Hazard Analysis for All Patients With KD and
Maximum Coronary Artery Z Score ≥2.5
Univariable
Risk Factors

HR

Lower
95% CI

Upper
95% CI

P Value

Maximum CAA Z score
≥2.5 to <10

0.19

0.09

0.42

<0.001

≥10 to <20

Reference

≥20 to <30

2.33

1.01

5.40

0.05

≥30

7.63

3.12

18.7

<0.001

No. of CAAs with Z score ≥10
1

0.05

0.02

0.16

<0.001

2

Reference

3

1.98

0.91

4.33

0.09

4

3.13

1.38

7.11

0.006

CAA indicates coronary artery aneurysm; HR, hazard ratio; KD, Kawasaki
disease.
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long-term and uninterrupted clinical follow-up. The
highest risks were associated with CAAs in the LAD and
RCA with maximum Z scores ≥20 and complex CAA
architecture. Luminal normalization of coronary artery
dimension was more likely to occur for CAAs in the
LAD and LCX branches, with the likelihood of normalization inversely related to the initial maximum Z score
of CAA. Additional factors such as IVIG treatment during the acute phase, lower erythrocyte sedimentation
rate, and lower total CAA area were also associated
with an increased likelihood of luminal normalization.
This study has the advantages of being a large, multiinstitutional, international study, which more precisely
defines the prevalence of CAA-related cardiovascular
complications, uses longitudinal Z scores, and defines
associations with coronary artery branch, with over a
10-year follow-up.

Risk Stratification
Manlhiot et al7 first demonstrated that, regardless of
absolute dimensions, a CAA Z score ≥10 represented
the effective lower bound of risk for cardiac complications in the medium term after KD. However, we found
that within groups with large CAAs (Z scores ≥10), the
risk profile of large aneurysms with Z scores <20 differs
significantly from aneurysms with Z scores ≥20, with
the latter being at substantially higher risk of complications. This is a novel finding that may have important
implications in the surveillance and management of patients with CAA Z scores ≥20. We, therefore, propose
that patients with CAAs that have Z scores ≥20 be further distinguished and be regarded as a separate and
higher risk category than those with CAAs that have
Z scores between ≥10 and <20. The change in risk
stratification has important implications for the intensity

Table 4. Characteristics of Coronary Artery Branches
With Aneurysms With Maximum Coronary Artery Z Score
≥10
Branch
RCA

297 (33%)

LMCA

91 (10%)

LAD

370 (42%)

LCX
Maximum coronary artery Z score

135 (15%)
Median (IQR) 15.7
(12.3–22.3)

10.0–19.9

603 (68%)

20.0–29.9

195 (22%)

30.0–39.9

48 (5%)

40.0+

47 (5%)

Involvement of the LAD/LMCA/LCX bifurcation
Yes

338 (38%)

No

555 (62%)

Aneurysm architecture
Isolated aneurysm in normal vessel

161 (18%)

Isolated aneurysm in a dilated vessel

332 (37%)

Complex aneurysms*

251 (28%)

Undefined/unreported

149 (17%)

Aneurysm location within branch
Proximal segment
Distal segment

343 (38%)
79 (9%)

Extending throughout segment

221 (25%)

Undefined/unreported

250 (28%)

Aneurysm shape
Saccular

171 (20%)

Fusiform/irregular

306 (34%)

Undefined/unreported

416 (47%)

Aneurysm diameter to height ratio (n=312)

Median (IQR) 0.73
(0.53–1.06)

Aneurysm estimated area (n=312)

Median (IQR) 0.72
(0.44–1.34)

IQR indicates interquartile range; LAD, left anterior descending artery;
LCX, left circumflex artery; LMCA, left main coronary artery; and RCA, right
coronary artery.
*Architecture other than a single isolated aneurysm in a coronary artery
branch.

and type of thromboprophylaxis that should be used in
those patients. In small (2.5≤Z<5) to medium (5≤Z≤10)
CAAs, where platelet activation is a key factor in initiating thrombus formation, antiplatelet therapy is likely to
be effective and is currently the mainstay of therapy.
However, more aggressive thromboprophylactic therapy with the addition of an anticoagulant is necessary
in patients with large (Z score ≥10, and even more so
in those with Z score ≥20) or progressive CAAs, where
the low shear stress environment and flow stasis leads
to activation of the clotting cascade.8
The 2017 AHA guidelines considered omitting
echocardiographic evaluation in children with small

J Am Heart Assoc. 2020;9:e016440. DOI: 10.1161/JAHA.119.0164408

McCrindle et al

Medium-Term Complications of Kawasaki Disease

Downloaded from http://ahajournals.org by on August 13, 2020
Figure 2. Cumulative incidence of luminal narrowing, coronary artery thrombosis, and normalization of luminal
diameter, calculated using Kaplan–Meier survival analysis, for coronary artery aneurysms after Kawasaki
disease in coronary artery branches with coronary artery Z score ≥10 stratified by coronary artery branches.
LAD indicates left anterior descending coronary artery; LCX, left circumflex artery; LMCA, left main coronary artery; RCA,
right coronary artery; and maximum coronary artery Z scores.
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Table 5. Multivariable Factors Associated With Risk Luminal Narrowing Using Cox Proportional Hazard Analysis in
Branches With CAAs With Z Score ≥10
Multivariable Risk Factors
Maximum CAA Z score

Reliability, %

HR

Lower 95% CI

Upper 95% CI

P Value

100

≥10 to <20

Reference

≥20 to <30

3.65

1.91

6.98

<0.001

≥30 to <40

4.24

2.00

9.01

<.0001
<0.001

7.56

3.19

17.9

No. of d of fever before IVIGs

≥40
98

1.04

1.01

1.07

0.01

Complex aneurysms architecture

97

1.93

1.24

3.01

0.004

Albumin level, g/L

94

0.92

0.86

0.98

0.008

No. of IVIG cycles

93

0

Reference

1

0.13

0.03

0.54

0.005

2

0.34

0.12

0.96

0.04

0.48

0.18

1.29

0.15

0.11

0.01

0.82

0.03

LAD

0.58

0.38

0.89

0.01

LCX

0.22

0.07

0.72

0.01

3+
Branch

78

RCA

Reference

LMCA

CAA indicates coronary artery aneurysm; HR, hazard ratio; IVIG, intravenous immunoglobulin; LAD, left anterior descending artery; LCX, left circumflex
artery; LMCA, left main coronary artery; and RCA, right coronary artery.
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aneurysms who had normalization of the dimension of
their coronary artery lumen (risk level 3.2). No patient
with small CAAs had cardiac complications during the
follow-up period, and 99% had normalization of their
CAA luminal diameter. Given our data and a previous
study by Dionne et al,9 which showed preserved endothelium continuity in patients with small CAAs but
no actual anatomical aneurysms (ie, dilatation only),
it would be reasonable to consider discharging these
patients from cardiology follow-up. This recommendation is currently only true for children with lower risk
levels (risk level 1 or 2).1 As cardiologists and whenever evidence supports, we ought to empower our patients to achieve their maximal potential and not leave
a cloud of being different for those with no evidence of

complications. Such a label might impact “self-image
and lifestyle.”10

Examination of Additional Risk Factors
While Manlhiot et al proposed a risk classification
system based solely on coronary artery Z scores,
we found evidence that branch-level factors play
an important role in determining the risk of luminal
narrowing and thrombosis, as well as the likelihood
of luminal diameter normalization.7 This supports
findings from Tsuda et al11 that branch CAAs had a
higher risk of stenosis compared with bifurcation aneurysms. Rheological studies have reported a strong
negative correlation between shear stress and risk of
thrombus formation.8,12 In angiographic studies with

Table 6. Multivariable Factors Associated With Risk Coronary Artery Thrombosis, Using Cox Proportional Hazard
Analysis, in Branches With CAAs With Z Score ≥10
Multivariable Risk Factors
Maximum CAA Z score

Reliability, %

HR

Lower 95% CI

Upper 95% CI

P Value

100

≥10 to <20

Reference

≥20 to <30

3.51

1.84

6.69

<0.001

≥30 to <40

5.74

2.50

13.16

<0.001

≥40

29.5

14.4

60.3

<0.001

Complex aneurysms architecture

88

2.08

1.32

3.26

0.002

Treatment with IVIG

87

0.38

0.19

0.76

0.006

C-reactive protein, 10 mg/L

76

0.95

0.90

0.99

0.02

CAA indicates coronary artery aneurysm; HR, hazard ratio; and IVIG, intravenous immunoglobulin.
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Figure 3. Cumulative incidence of normalization of luminal
diameter, calculated using Kaplan–Meier survival analysis,
for coronary artery aneurysms (CAAs) after Kawasaki
disease stratified by level of coronary artery involvement.

Doppler flow, the average peak velocity in the CAA
was found to decrease as the size of the CAA increased, suggesting that flow stagnation was also a
risk factor for thrombosis.12–16

In our analysis of CAA architecture, we found that
both a higher number of CAAs within a coronary
artery branch, and CAAs of the LAD/LCX involving
the left bifurcation, increased the risk of complications in patients with large CAAs. Interestingly, research on atherosclerotic heart disease has found
that the localization of atherosclerotic lesions to certain areas within the arterial system, particularly the
branching sites, could be associated with rheological
characteristics.14,15
In terms of CAA location, the risk of thrombosis
and luminal narrowing was higher in CAAs affecting the RCA and LAD coronary artery branches. We
speculate that this could be a result of several reasons. First, reliability of LMCA measurements has
been of concern, because of its anatomical variation.17 Second, being short and high-pressured, the
walls of the LMCA may be less likely to weaken and
facilitate sluggish flow. In terms of the LCX branch,
its distal anatomical placement hinders visualization
by echocardiography, which creates the possibility
that stenosis and thrombus development in the area
were missed.
Taken together, our findings support that these
additional coronary artery branch–level risk factors should be taken into account when decisions
are made regarding risk classification. While we
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Table 7. Multivariable Factors Associated With Risk of Normalization of Luminal Diameter, Using Cox Proportional Hazard
Analysis, in Branches With CAAs With Z Score ≥10
Multivariable Risk Factors
Maximum CAA Z score

Reliability, %

HR

Lower 95% CI

Upper 95% CI

P Value

100

≥10 to <20

Reference

≥20 to <30

0.50

0.38

0.66

0.002

≥30 to <40

0.24

0.12

0.51

<0.001

0.25

0.10

0.61

<0.001

>1.35

7.01

2.38

20.6

<.001

0.71 to 1.35

4.50

1.61

12.6

0.004

1.59

0.46

5.58

0.47

≥40
Aneurysm area, cm2

100

0.46 to 0.70
≤0.45
Branch

Reference
99

RCA

Reference

LMCA

0.60

0.39

0.91

0.02

LAD

1.94

1.51

2.48

<.001
<.001

2.16

1.55

3.00

Treatment with IVIGs

LCX
94

3.22

1.28

8.13

0.01

Age at acute KD, y

94

0.93

0.89

0.97

0.006

Incomplete KD

85

1.31

0.99

1.73

0.056

ESR, 10 mm/h

78

0.95

0.91

0.99

0.03

Women

67

1.33

1.03

1.72

0.03

CAA indicates coronary artery aneurysm; ESR, erythrocyte sedimentation rate; HR, hazard ratio; IVIG, intravenous immunoglobulin; KD, Kawasaki disease;
LAD, left anterior descending artery; LCX, left circumflex artery; LMCA, left main coronary artery; and RCA, right coronary artery.
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conclude that CAA architecture was an important
feature to include for risk stratification, we did not
find any association between CAA shape (saccular
versus fusiform) and any of the cardiac complications
considered in this study, despite this finding being reported in previous studies. This could be associated
with the fact that almost half of all imaging reports did
not indicate the shape of the CAAs and, as such, the
number of missing data were substantial to identify
a pattern. The development and utilization of better
methods to characterize CAA lesions would be an
important next step to further refine risk stratification
models.

Outcome Comparisons With Previous
Studies
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In a 10- to 21-year follow-up study by Kato et al4 of 146
patients with KD and CAAs, 90% of patients showed
normalization of luminal dimensions within the first
2 years from onset; however, none of the large or giant
CAAs, defined as having an absolute diameter of at
least 8 mm, showed normalization of luminal dimension. A study from the United States by Friedman et
al18 found an overall CAA proportion of normalization
of luminal dimensions of 75%, which they believed was
higher than those reported in previous cohorts attributable to more aggressive treatment. Similar to Kato et al,
they also found that the probability of normalization of
luminal dimensions was inversely proportional to CAA
Z score at diagnosis.18 This was in line with our findings, with >80% of small to medium CAAs and ≈50% of
large CAAs achieving luminal diameter normalization.
Friedman et al also reported that major adverse cardiovascular events occurred exclusively in large CAAs,
which was similar to our findings, where all complications occurred in patients with large CAAs, with the exception of 1 patient with medium CAAs who had CAAs
in all 4 branches. In our study, the rate of CAA normalization was similar to Friedman et al and larger than Kato
et al (55%–60%), which speaks to potentially more aggressive management in the current era. However, the
rate of luminal narrowing for large CAAs with Z score
≥10 at ≈20% was similar to the data from Kato et al4
(despite the different definitions of large CAAs), indicating a need for more aggressive management and/or
novel approaches in this patient population.

Medium-Term Complications of Kawasaki Disease

correlation between 0.60 and 0.75 for all segments
other than the circumflex) between coronary artery
segment dimensions measured at local centers versus core laboratory assessment in this context.19
Regardless of the method of interpretation, echocardiography is inferior to advanced imaging modalities
(eg, computed tomography, magnetic resonance imaging, or invasive angiography) in estimating coronary
artery diameter, particularly the distal coronary artery
tree, although it is still the standard of care for most
patients. Not all patients had such advanced imaging
studies (1% of patients with small CAAs, 5% to 8% of
patients with medium CAAs, and ≈50% of patients
with large CAAs divided roughly equally between
angiography and magnetic resonance imaging). In
terms of coronary artery branch anatomy, assessment based on reports was required to obtain features, which is subject to interpretation error. Another
source of variation is that outcomes were often detected at the time of imaging rather than when they
actually occurred, particularly when asymptomatic.
Last, our study design was retrospective, and there
was no auditing of data at centers, so we cannot exclude the possibility of selection bias in cases submitted, although this would be unlikely.

CONCLUSIONS
In this large, multi-institutional international study conducted in patients with KD who had CAAs, we report
that the risks of luminal narrowing, thrombosis, and
major adverse cardiovascular complications were
nearly completely confined to those with maximum
CAA Z scores ≥10. We can also propose that CAAs
with Z scores ≥20 should now be considered a separate risk strata because of their distinctly greater risk
profile. The presence of complex CAAs, as well as the
involvement of LAD and RCA branches, increases an
individual’s risk for CAA-related complications, and
these factors should be taken into account on an individual basis when considering surveillance and management strategies. Future studies could focus on
rheology to investigate patient-specific hemodynamic
factors, which could increase the risk of complications and assess the effectiveness of more aggressive
thromboprophylactic regimens, including triple therapy, in patients with CAAs with Z scores ≥20.

Limitations
This study used echocardiography reports rather
than an imaging core laboratory; thus, differences
in methods of measurement by participating cardiologists may have contributed to data variability. A
secondary analysis of the Pediatric Heart Network’s
randomized Kawasaki disease trial has previously
shown moderately good agreement (interclass

APPENDIX
The members of the International Kawasaki Disease
Registry include: Carolyn A. Altman MD—Texas
Children’s Hospital, Baylor College of Medicine,
Houston, TX; Brett R. Anderson MD—Columbia
University, College of Physicians and Surgeons, New
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York, NY; Emilie Beaulieu MD—Centre de Recherche
du Centre Hospitalier Universitaire de Sherbrooke,
Sherbrooke, Quebec, Canada; Carolyn E. Boychuk
BSc—Stollery Children’s Hospital, Edmonton, Alberta,
Canada; Elizabeth Braunlin MD, PhD—University of
Minnesota, Minneapolis, MN; Jane C. Burns MD—
Department of Pediatrics, University of California
San Diego, Rady Children’s Hospital-San Diego,
CA; Michael R. Carr MD—Ann and Robert H. Lurie
Children’s Hospital of Chicago, IL; Andrew Crean MRCP,
MPH—Toronto General Hospital, Toronto, Ontario,
Canada; Jessica H. Colyer MD—Pediatrics Cardiology,
Children’s National Health System/George Washington
University, Washington, DC; Adam Dempsey PhD—
Department of Paediatrics, Western University, London,
Ontario, Canada; Laurent Desjardins MD—Division of
Pediatric Cardiology, Centre Hospitalier Universitaire
Ste-Justine, University of Montreal, Quebec, Canada;
Rejane Dillenburg MD—McMaster Children’s Hospital,
Hamilton, Ontario, Canada; Audrey Dionne MD—
Division of Pediatric Cardiology, Centre Hospitalier
Universitaire Ste-Justine, University of Montreal,
Quebec, Canada; Anna Ferris MBBS—Columbia
University - College of Physicians and Surgeons, New
York, NY; Michael Gewitz MD—Maria Fareri Children’s
Hospital at Westchester Medical Center (WMC)
Health, New York Medical College, Valhalla, New York;
Michelle M. Grcic RN, MSN, CNP—The Heart Center at
Nationwide Children’s Hospital, Columbus, OH; Steven
C. Greenway MD—Alberta Children’s Hospital, Calgary,
Alberta, Canada; Kevin C. Harris MD, MHSc—Children’s
Heart Centre, University of British Columbia, Vancouver,
British Columbia; Christina Hayden-Rush BSN—The
Children’s Hospital of Philadelphia, Philadelphia, PA;
Kevin D. Hill MD—Duke University Medical Center,
Durham, NC; Supriya Jain MD—Maria Fareri Children’s
Hospital at Westchester Medical Center (WMC) Health,
New York Medical College, Valhalla, New York; Thomas
R. Kimball MD—Heart Institute, Cincinnati Children’s
Hospital Medical Center, Cincinnati, OH; Sean M.
Lang MD—Heart Institute, Cincinnati Children’s
Hospital Medical Center, Cincinnati, OH; Ming-Tai Lin
MD, PhD—National Taiwan University, Taipei, Taiwan;
William T. Mahle MD—Children’s Healthcare of Atlanta,
GA; Tapas Mondal MD—McMaster Children’s Hospital,
Hamilton, Ontario, Canada; Michael A. Portman MD—
Seattle Children’s Research Institute, Seattle, WA;
Claudia Renaud MD—Montreal Children’s Hospital,
McGill University, Montreal, Quebec, Canada; S.
Kristen Sexson Tejitel MD, PhD, MPH—Texas Children’s
Hospital, Baylor College of Medicine, Houston, TX;
Jacqueline R. Szmuszkovicz MD—Children’s Hospital
of Los Angeles, CA; Karen M. Texter MD—The Heart
Center at Nationwide Children’s Hospital, Columbus,
OH; Deepika Thacker MD—Nemours Cardiac Center,
Nemours/Alfred I. duPont Hospital for Children,
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New Castle County, DE; Elif Seda Selamet Tierney
MD—Division of Pediatric Cardiology, Department of
Pediatrics, Stanford University, School of Medicine, Palo
Alto, CA; Thomas Thomas MD—Pediatric Cardiology,
Children’s Hospital Colorado, University of Colorado
School of Medicine, Aurora, CO; Adriana H. Tremoulet
MS, MAS—Department of Pediatrics, University of
California San Diego, Rady Children’s Hospital-San
Diego, CA; Sharon Wagner-Lees RN-BC, BSN, MBA—
Children’s Hospital of Los Angeles, CA; Andrew Warren
MD—IWK Health Centre, Halifax, Nova Scotia, Canada.
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